Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
RAPAFLO Silodosin Benign prostatic hyperplasia Do not list Complete
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque List with clinical criteria and/or conditions Complete
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque N/A Complete
Rasilez Aliskiren Hypertension Do not list Complete
Ravicti glycerol phenylbutyrate Urea cycle disorders Reimburse with clinical criteria and/or conditions Complete
Rebif Interferon beta-1a Clinically isolated syndrome Do not list Complete
Reblozyl luspatercept beta-thalassemia associated anemia Reimburse with clinical criteria and/or conditions Complete
Reblozyl luspatercept Myelodysplastic syndromes-associated anemia Reimburse with clinical criteria and/or conditions Complete
Relistor Methylnaltrexone bromide Constipation, Opioid-induced Do not list Complete
Relpax Eletriptan hydrobromide Migraine Do not list Complete
Remicade Infliximab Ulcerative Colitis Do not list Complete
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) Do not list Complete
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) List with clinical criteria and/or conditions Complete
Remsima infliximab Rheumatoid arthritis Reimburse with clinical criteria and/or conditions Complete
Remsima infliximab Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete
Remsima infliximab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete
Remsima Infliximab Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis Withdrawn
Renflexis infliximab rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Reimburse with clinical criteria and/or conditions Complete
Repatha Evolocumab Primary hyperlipidemia and mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete
Repatha evolocumab Primary hyperlipidemia Reimburse with clinical criteria and/or conditions Active
Repatha Evolocumab Primary hyperlipidemia; mixed dyslipidemia List with clinical criteria and/or conditions Complete
Replagal Agalsidase alfa Fabry Disease Do not list Complete
Resotran Prucalopride Constipation, chronic Do not list Complete
Restasis ophthalmic emulsion Cyclosporine Dry eye disease Do not list Complete
Retevmo selpercatinib RET fusion-positive non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete